Biohaven Ltd. Common Shares (BHVN)
Stock · NYSE · Health Care
$10.8as of 10/16/2026
Price chart
Active signals
BHVN Signal Track Record
How signals performed across all stocks →What BHVN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 31 | 0.0% | 48% | September 17, 2026 |
| Bollinger Band Breakout | 20 | -0.4% | 45% | August 26, 2026 |
| Bollinger Band Breakdown | 15 | -7.8% | 33% | March 6, 2026 |
| 200-Day Moving Average TouchActive now | 5 | -1.8% | 20% | October 6, 2026 |
| Any 20-session window (baseline) | -0.1% | 50% |
Computed by MarketWall from daily closing prices since July 12, 2023. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About BHVN
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 274
- Website
- www.biohaven.com/
Fundamentals
- 1-day range
- $10.71$11.4
- Market cap
- $2.17B
- P/E (trailing)
- —
- P/E (forward)
- -5.76
- EPS (trailing)
- $-4.64
- Dividend yield
- —
- Beta
- 3.18
- Avg. volume
- 2.62M
How Biohaven Ltd. Common Shares Makes Money
Where the revenue actually goes — FY2021 annual results
Source: 10-K filed Feb 25, 2022 · via SEC EDGAR / Finnhub
Forecasts
15 analyst ratings
Biohaven Ltd. Common Shares Competitors
Chosen by industry and closest market cap.
- BHVNBiohaven Ltd. Common Shares$10.78▼ 5.69%Market cap $2.17BP/E —$7.48$18.57
- SLSSELLAS Life Sciences Group Inc. Common Stock$9.98▼ 11.99%Market cap $2.18BP/E —$1.39$15.88
- BHCBausch Health Companies Inc. Common Stock$6.3▼ 0.16%Market cap $2.21BP/E —$6.1$11.08
- NUVBNuvation Bio Inc. Class A Common Stock$4.45▼ 6.32%Market cap $2.13BP/E —$3.36$9.75
- RAPPRapport Therapeutics Inc. Common Stock$27.57▼ 6.76%Market cap $2.22BP/E —$23.75$52.93
- URGNUroGen Pharma Ltd. Ordinary Shares$34.56▼ 5.60%Market cap $2.22BP/E —$16.37$50.81
- MLYSMineralys Therapeutics Inc. Common Stock$20.3▼ 6.19%Market cap $2.23BP/E —$21.46$47.65
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BHVN Biohaven Ltd. Common Shares | $2.17B | — | $10.78 | ▼ 5.69% | $7.48$18.57 |
| SLS SELLAS Life Sciences Group Inc. Common Stock | $2.18B | — | $9.98 | ▼ 11.99% | $1.39$15.88 |
| BHC Bausch Health Companies Inc. Common Stock | $2.21B | — | $6.3 | ▼ 0.16% | $6.1$11.08 |
| NUVB Nuvation Bio Inc. Class A Common Stock | $2.13B | — | $4.45 | ▼ 6.32% | $3.36$9.75 |
| RAPP Rapport Therapeutics Inc. Common Stock | $2.22B | — | $27.57 | ▼ 6.76% | $23.75$52.93 |
| URGN UroGen Pharma Ltd. Ordinary Shares | $2.22B | — | $34.56 | ▼ 5.60% | $16.37$50.81 |
| MLYS Mineralys Therapeutics Inc. Common Stock | $2.23B | — | $20.3 | ▼ 6.19% | $21.46$47.65 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell RightsYahoo · 10/10/2026
- Biohaven partners with Ono in $100m IgG degrader dealYahoo · 10/9/2026
- Biohaven Expands Asian Licensing Footprint Through Strategic Ono Agreementbenzinga · 10/8/2026
- Biohaven Expands Asian Licensing Footprint Through Strategic Ono AgreementBenzinga · 10/8/2026
- Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' DiseaseYahoo · 10/8/2026
- Is Biohaven (BHVN) Quietly Recasting Its Oncology Strategy Through Deeper Ties With Regeneron?Yahoo · 10/8/2026
- Biohaven Licenses MoDE IgG Degraders To Ono For Japan, South Korea, Taiwan And ASEAN For Up To $100M Near-Term Payments Including $80M Upfront; BHV-1300 In Phase 3 For Graves' DiseaseBenzinga · 10/8/2026
- Roche’s AI lab; Biohaven’s pivotal pauseYahoo · 10/2/2026
- Why Did Regeneron Pharmaceuticals (REGN) Stock Drop Today?Yahoo · 9/29/2026
Insider Activity
Insider Actions →- Gentile Kimberly · September 15, 2026 · Grant1.0K
- Antonijevic Irina · April 28, 2026 · Grant68.7K
- Mehta Kishan · April 28, 2026 · Grant68.7K
- Heffernan Michael Thomas · April 28, 2026 · Grant68.7K
- Gregory Bailey · April 28, 2026 · Grant68.7K
- HUGIN ROBERT J · April 28, 2026 · Grant68.7K
- GREGORY JULIA P · April 28, 2026 · Grant68.7K
- John W. Childs · April 28, 2026 · Grant68.7K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Biohaven signs $100M deal with Ono for IgG degraders
Biohaven has entered a strategic licensing agreement with Ono Pharma for its IgG degrader technology in Japan and select Asian regions. The deal includes up to $100 million in near-term payments, with $80 million paid upfront. This move expands the company's presence in Asia and supports its lead candidate, BHV-1300, which is currently in Phase 3 trials for Graves' disease.
Biohaven signs $100M deal with Ono for IgG degraders. Biohaven has entered a strategic licensing agreement with Ono Pharma for its IgG degrader technology in Japan and select Asian regions. The deal includes up to $100 million in near-term payments, with $80 million paid upfront. This move expands the company's presence in Asia and supports its lead candidate, BHV-1300, which is currently in Phase 3 trials for Graves' disease.